Loading...
Loading...
Senesco Technologies, Inc. (“Senesco” or the “Company”)
SNT
announced today the results from the completed non-clinical study of SNS01-T
in combination of lenalidomide in a model of multiple myeloma. Combining
SNS01-T treatment with lenalidomide (the active ingredient in REVLIMID^®
marketed by Celgene Corporation) inhibits tumor growth more effectively than
either drug alone. All mice treated with the combination survived over 100
days to the end of the study. Tumors were eradicated after a single 6-week
cycle of the combination in two thirds of the animals, and there was no
regrowth after an additional 8 weeks without further treatment.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in